Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes

João Coelho1, Luísa Malheiro1, João Melo Beirão1,2, Angelina Meireles1,2, Bernardete Pessoa1,2 1Unit of Ophthalmology, Centro Hospitalar Universitário Do Porto, Porto, Portugal; 2Unit of Ophthalmology, Universidade Do Porto-Instituto Ci&ecir...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Coelho J, Malheiro L, Melo Beirão J, Meireles A, Pessoa B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	diabetic macular edema fluocinolone acetonide dexamethasone implant intravitreal implants real-world vitrectomy Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/7d332ae5de2a45b99615deb965cb1585
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7d332ae5de2a45b99615deb965cb1585
record_format	dspace
spelling	oai:doaj.org-article:7d332ae5de2a45b99615deb965cb15852021-12-02T07:55:18ZReal-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes1177-5483https://doaj.org/article/7d332ae5de2a45b99615deb965cb15852019-09-01T00:00:00Zhttps://www.dovepress.com/real-world-retrospective-comparison-of-019-mg-fluocinolone-acetonide-a-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483João Coelho1, Luísa Malheiro1, João Melo Beirão1,2, Angelina Meireles1,2, Bernardete Pessoa1,2 1Unit of Ophthalmology, Centro Hospitalar Universitário Do Porto, Porto, Portugal; 2Unit of Ophthalmology, Universidade Do Porto-Instituto Ciências Biomédicas Abel Salazar, Porto, PortugalCorrespondence: João CoelhoUnit of Ophthalmology, Centro Hospitalar Universitário do Porto, Largo Prof. Abel Salazar, Porto 4099-001, PortugalTel +351 91 765 6826Email joaomsmc@gmail.comPurpose: The aim of this study was to evaluate the long-term real-world effectiveness of FAc and DEX implants in vitrectomized DME eyes in a real-world setting.Methods: This was a non-interventional, retrospective, comparative study of 46 vitrectomized eyes in 33 patients with persistent or recurrent DME quantified best-corrected visual acuity (BCVA), central foveal thickness (CFT) and intraocular pressure (IOP) over up to 37 months.Results: Both FAc and DEX treatment led to statistically and clinically significant improvements in BCVA and CFT. FAc >10-letter improvement on the Early Treatment Diabetic Retinopathy Study [ETDRS] chart over months 3–24 and a sustained &sim;200 μm CFT reduction over months 1–24; DEX: >5-letter improvement on the ETDRS chart at months 1 and 3 and >100 μm CFT reduction at month 1. FAc demonstrated sustained, stable and predictable effects on BCVA and CFT over 24 months and also improved BCVA and decreased CFT in a cohort of DME eyes that was refractory to DEX over 6 months.Conclusion: This real-world study demonstrates long-term effectiveness of FAc in vitrectomized DME eyes and sustained effectiveness in DME eyes that did not respond to DEX therapy.Keywords: diabetic macular edema, fluocinolone acetonide, dexamethasone implant, intravitreal implants, real-world, vitrectomyCoelho JMalheiro LMelo Beirão JMeireles APessoa BDove Medical Pressarticlediabetic macular edemafluocinolone acetonidedexamethasone implantintravitreal implantsreal-worldvitrectomyOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 1751-1759 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	diabetic macular edema fluocinolone acetonide dexamethasone implant intravitreal implants real-world vitrectomy Ophthalmology RE1-994
spellingShingle	diabetic macular edema fluocinolone acetonide dexamethasone implant intravitreal implants real-world vitrectomy Ophthalmology RE1-994 Coelho J Malheiro L Melo Beirão J Meireles A Pessoa B Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
description	João Coelho1, Luísa Malheiro1, João Melo Beirão1,2, Angelina Meireles1,2, Bernardete Pessoa1,2 1Unit of Ophthalmology, Centro Hospitalar Universitário Do Porto, Porto, Portugal; 2Unit of Ophthalmology, Universidade Do Porto-Instituto Ciências Biomédicas Abel Salazar, Porto, PortugalCorrespondence: João CoelhoUnit of Ophthalmology, Centro Hospitalar Universitário do Porto, Largo Prof. Abel Salazar, Porto 4099-001, PortugalTel +351 91 765 6826Email joaomsmc@gmail.comPurpose: The aim of this study was to evaluate the long-term real-world effectiveness of FAc and DEX implants in vitrectomized DME eyes in a real-world setting.Methods: This was a non-interventional, retrospective, comparative study of 46 vitrectomized eyes in 33 patients with persistent or recurrent DME quantified best-corrected visual acuity (BCVA), central foveal thickness (CFT) and intraocular pressure (IOP) over up to 37 months.Results: Both FAc and DEX treatment led to statistically and clinically significant improvements in BCVA and CFT. FAc >10-letter improvement on the Early Treatment Diabetic Retinopathy Study [ETDRS] chart over months 3–24 and a sustained &sim;200 μm CFT reduction over months 1–24; DEX: >5-letter improvement on the ETDRS chart at months 1 and 3 and >100 μm CFT reduction at month 1. FAc demonstrated sustained, stable and predictable effects on BCVA and CFT over 24 months and also improved BCVA and decreased CFT in a cohort of DME eyes that was refractory to DEX over 6 months.Conclusion: This real-world study demonstrates long-term effectiveness of FAc in vitrectomized DME eyes and sustained effectiveness in DME eyes that did not respond to DEX therapy.Keywords: diabetic macular edema, fluocinolone acetonide, dexamethasone implant, intravitreal implants, real-world, vitrectomy
format	article
author	Coelho J Malheiro L Melo Beirão J Meireles A Pessoa B
author_facet	Coelho J Malheiro L Melo Beirão J Meireles A Pessoa B
author_sort	Coelho J
title	Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
title_short	Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
title_full	Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
title_fullStr	Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
title_full_unstemmed	Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
title_sort	real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/7d332ae5de2a45b99615deb965cb1585
work_keys_str_mv	AT coelhoj realworldretrospectivecomparisonof019mgfluocinoloneacetonideand07mgdexamethasoneintravitrealimplantsforthetreatmentofdiabeticmacularedemainvitrectomizedeyes AT malheirol realworldretrospectivecomparisonof019mgfluocinoloneacetonideand07mgdexamethasoneintravitrealimplantsforthetreatmentofdiabeticmacularedemainvitrectomizedeyes AT melobeiraoj realworldretrospectivecomparisonof019mgfluocinoloneacetonideand07mgdexamethasoneintravitrealimplantsforthetreatmentofdiabeticmacularedemainvitrectomizedeyes AT meirelesa realworldretrospectivecomparisonof019mgfluocinoloneacetonideand07mgdexamethasoneintravitrealimplantsforthetreatmentofdiabeticmacularedemainvitrectomizedeyes AT pessoab realworldretrospectivecomparisonof019mgfluocinoloneacetonideand07mgdexamethasoneintravitrealimplantsforthetreatmentofdiabeticmacularedemainvitrectomizedeyes
_version_	1718399109504696320

Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes

Ejemplares similares